Prediction of Getting Peripheral Neuropathy in Patients Treated With Bortezomib? - Trial NCT05781425
Access comprehensive clinical trial information for NCT05781425 through Pure Global AI's free database. This phase not specified trial is sponsored by Odense University Hospital and is currently Not yet recruiting. The study focuses on Chemotherapy-induced Peripheral Neuropathy. Target enrollment is 20 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Observational
Sponsor & Location
Odense University Hospital
Timeline & Enrollment
N/A
Apr 01, 2023
Dec 31, 2023
Primary Outcome
Level of plasma neurofilament light chain,Level of plasma neurofilament light chain,Level of plasma neurofilament light chain,Level of plasma neurofilament light chain,Level of plasma neurofilament light chain,Level of plasma neurofilament light chain,Level of plasma neurofilament light chain,Level of plasma neurofilament light chain,Level of plasma neurofilament light chain,Level of plasma neurofilament light chain
Summary
Investigation of which patients treated with bortezomib that have increased risk of
 developing peripheral neuropathy.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05781425
Non-Device Trial